Literature DB >> 15983291

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

Fiona Turnbull1, Bruce Neal, Charles Algert, John Chalmers, Neil Chapman, Jeff Cutler, Mark Woodward, Stephen MacMahon.   

Abstract

BACKGROUND: Blood pressure (BP) level is a major determinant of cardiovascular morbidity and mortality in individuals with diabetes mellitus. Several guidelines recommend lower BP goals and specific drug classes for these patients. The overviews reported herein were performed to formally compare the effects on cardiovascular events and death of different BP-lowering regimens in individuals with and without diabetes.
METHODS: Twenty-seven randomized trials (N = 158 709 participants) that included 33 395 individuals with diabetes and 125 314 without diabetes contributed to these analyses. For each outcome and each comparison summary, estimates of effect and 95% confidence intervals were calculated for patients with and without diabetes using a random-effects model. The constancy of the effects of each treatment regimen in participants with and without diabetes was examined using chi(2) tests of homogeneity.
RESULTS: Total major cardiovascular events were reduced to a comparable extent in individuals with and without diabetes by regimens based on angiotensin-converting enzyme inhibitors, calcium antagonists, angiotensin receptor blockers, and diuretics/beta-blockers (P > .19 for all by chi(2) test of homogeneity). There was limited evidence that lower BP goals produced larger reductions in total major cardiovascular events in individuals with vs without diabetes (P = .03 by chi(2) test of homogeneity).
CONCLUSIONS: These overviews showed that the short- to-medium-term effects on major cardiovascular events of the BP-lowering regimens studied were broadly comparable for patients with and without diabetes. Different effects of regimens on intermediate renal outcomes not evaluated in these overviews may still provide a rationale for using specific drug classes in patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983291     DOI: 10.1001/archinte.165.12.1410

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  194 in total

Review 1.  Intracardiac intracellular angiotensin system in diabetes.

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas; Kenneth M Baker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

2.  2011 Canadian Hypertension Education Program recommendations: an annual update.

Authors:  Norm Campbell
Journal:  Can Fam Physician       Date:  2011-12       Impact factor: 3.275

3.  Hypertension control in patients with diabetes.

Authors:  Jacky T P Siu; Aaron M Tejani; Vijaya Musini; Ken Bassett; Barbara Mintzes; Jim Wright
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

Review 4.  Annual adult health checkup: update on the Preventive Care Checklist Form(©).

Authors:  Anthony Duerksen; Vinita Dubey; Karl Iglar
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

5.  The changing role of hypertension societies: shifting gears in Italy.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2012-03-01

6.  2010 Canadian Hypertension Education Program recommendations: An annual update.

Authors:  Norm Campbell; Margaret Moy Lum Kwong
Journal:  Can Fam Physician       Date:  2010-07       Impact factor: 3.275

7.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

Review 8.  Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.

Authors:  Massimo Volpe; Roberto Pontremoli; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-09-01

Review 9.  Blood pressure lowering in patients with diabetes--one level might not fit all.

Authors:  Rhonda M Cooper-DeHoff; Eric F Egelund; Carl J Pepine
Journal:  Nat Rev Cardiol       Date:  2010-11-16       Impact factor: 32.419

10.  Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing?

Authors:  Eve A Kerr; Michelle A Lucatorto; Rob Holleman; Mary M Hogan; Mandi L Klamerus; Timothy P Hofer
Journal:  Arch Intern Med       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.